We currently have several clinical research studies at our site for the following indications:

CURRENT STUDIES

ALZHEIMER’S/DEMENTIA

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of CNP520 in Participants at Risk of the Onset of Clinical Symptoms of Alzheimer’s Disease (AD) (CCNP520A2202J GENERATION 2)


Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD) (l7S-MC-HBEH)

MIGRAINE


A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraines. (BHV3500-201)


A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine

(ALD403-CLIN-015)

MULTIPLE SCLEROSIS

Long-Term, Prospective, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS Newly Started on Fingolimod Once Daily or Treated with Another Approved Disease-Modifying Therapy (CFTY720D2403 PASSAGE)


A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera When Using in Routine Medical Practice in the Treatment of Multiple Sclerosis (109MS401 ESTEEM)


A Prospective, Multicenter, Observational, Post-Authorization Safety Study (PASS) to Evaluate the Long-Term Safety Profile of LEMTRADA (alemtuzumab) Treatment in Patients with Relapsing Forms of Multiple Sclerosis (OBS13434)


A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis (RPC01-3001 RECEPTOS)


A Open-Label, Single Arm, Multi-Center Extension Study Evaluating Long-Term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects with Relapsing Multiple Sclerosis (COMB157G2399)

PARKINSON’S

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson’s Disease (CLR_18_06)

Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson’s Disease Dementia (PDD) (l7S-MC-HBEH)


05.19.19

To enroll in any of the above studies or to find out more information, please call Susie at 720-588-2557, email at [email protected] or click the link below to fill out a contact form.